DOYLESTOWN, PA--(MARKET WIRE)--Jul 31, 2007 -- QuantRx® Biomedical Corporation (OTC BB:QTXB.OB - News), an emerging leader in the research and development of medical diagnostic platforms and products, today announced that FluoroPharma, its majority owned affiliate, and a company developing breakthrough cardiovascular PET molecular imaging diagnostics, has made several recent additions to its management and scientific leadership team, including Dr. Todd R. Nelson as an Independent Director and Dr. Elazer Edelman as a Scientific Advisory Board member.
